Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its pipeline includes oral TYK2 inhibitors such as envudeucitinib for plaque psoriasis and systemic lupus erythematosus, plus a CNS-penetrant TYK2 program and lonigutamab for thyroid eye disease. The company uses a precision, data-driven approach from its base in South San Francisco.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 17.4 | — | -99 | — |
| Q2 2025 | 2.7 | — | 59.3 | — |
| Q3 2025 | 2.1 | — | -110.8 | — |
| Q4 2025 | 1.9 | — | -92.9 | — |
| Q1 2026 | 1.7 | -90% | -93 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Upstart Holdings, Inc. (UPST), Adeia Inc. (ADEA), Alignment Healthcare, Inc. (ALHC), McGrath RentCorp (MGRC), Axogen, Inc. (AXGN), AtaiBeckley Inc. (ATAI)